Late Phase Drug Development World 2011 - Speaker list

Dr. Enrica Alteri received her Medical Doctorate from the University La Sapienza in Rome, Italy. She completed a post-doctoral Fellowship in the Department of Immunopathology of the National Cancer Institute (USA). A Diploma in Pharmaceutical Medicine completed...

Andrew is Senior Director, Analytics Team Lead in Epidemiology at Pfizer Inc. This position oversees the provision of methodological and analytic expertise to the Epidemiology group in support of drug development and safety evaluation activities worldwide. Prior to...

Neil qualified from the London Hospital Medical College (University of London) in 1991 and gained Membership of the Royal College of Physicians in 1994. In October 2000, Neil entered the Pharmaceutical industry, initially in Medical Affairs roles in UCB Pharma UK...

Dr. Cassino is Vice President of the Medicines Development Group for Pulmonary Vascular Disease (PVD) and Rare Diseases at Pfizer Inc. in NY. In this capacity, she leads a global team responsible for worldwide clinical development and medical affairs...

As Global Product Strategist for Late Phase and ePRO, Scott Dixon focuses on product development and the operational aspects of late phase research and ePRO. Mr. Dixon was in a similar capacity at Phase Forward prior to its acquisition by Oracle. Previous to...

Elizabeth Hernberg-Ståhl has almost 20 years of international experience from Pharmaceutical Industry in developing and managing global patient registries on rare orphan diseases. She has during these years gained an in-depth expertise in designing and managing...

Pharmaceutical physician with over 20 years in various R/D functions including clinical research, medical affairs, pharmacovigilance, strategic product development and general management. Lecturer in drug development at King’s College, London.

Yue KANG, M.D., M.Sc, Affiliate Medical Director, Abbott Laboratories China, since 2008. Responsible for the medical department performance, including clinical research (ph 1~4); medical affairs; drug safety, medical information, medical operation, and...

• >20 years direct experience in pharmaceutical development, specialising in neurosciences and late stage drug development • Career has evolved through neuropharmacology research scientist, to clinical development, project management and leadership of pharmaceutical...

Paul Reilly has been active in clinical research in the pharmaceutical industry for over 30 years, most of the time with Boehringer Ingelheim. He has been active in both corporate and operational roles in Canada, Europe and the United States. He has planned and...

Dr. Florian Turk is Executive Director and Global Head Health Economics & Outcomes Research, Cardiovascular and Metabolism Business Franchise, Global Product Strategy & Commercialization at Novartis Pharma AG in Basel, Switzerland. Dr. Florian Turk is an experienced...